乳腺浸润性导管癌组织中Sox2的表达与临床病理因素及预后的相关性研究

 目的 探讨Sox2在乳腺浸润性导管癌组织中的表达及其与临床病理因素和预后的相关性。方法 采用免疫组织化学方法（Envision染色）检测138例乳腺浸润性导管癌及其配对癌旁正常乳腺组织中Sox2的表达水平，运用 χ 2检验和kaplan-Meier法分析肿瘤组织Sox2与临床病理因素及患者总生存时间的关系。结果 Sox2在乳腺癌组织和正常组织中的表达有显著性差异（ P <0.01）；Sox2在乳腺癌中的表达与组织学分级（ P =0.015）、淋巴结转移（ P =0.010）、肿瘤-淋巴结-远处转移分期（tumor-lymph node-metastasis stage, TNM）（ P =0.038）、人表皮生长因子-2（HER-2）的状态（ P =0.031）及术后5年生存率（ P =0.018）均有显著相关性；与患者年龄、肿瘤直径大小以及雌激素受体、孕激素受体的状态无显著相关性。结论 Sox2的表达可能参与了乳腺癌的发生、发展过程，其表达与临床病理因素及预后有一定关系，其很可能成为潜在的治疗靶点及判断乳腺癌预后的有价值的肿瘤标记物。

Correlation between Sox2 expression and clinicopathological factors and prognosis in patients with breast carcinoma

Objective To investigate the correlation between Sox2 expression and clinicopathological factors and prognosis in patients with breast carcinoma.Methods Immunnohistochemistry was used to analyze the Sox2 expression in 138 cases of breast carcinoma and adjacent normal breast tissues.The relationship between Sox2 expression and clinicopathological factors was analyzed using Chi-square test.Survival curves were generated according to the Kaplan-Meier method.Results The difference in Sox2 expression between breast carcinoma and adjacent normal breast tissues was statistically significant(P<0.01).The Sox2 expression was significantly correlated with histological grading(P=0.015),maxillary lymph node matastasis(P=0.010),TNM staging(P=0.038),HER-2 positive(P=0.031)and lower 5-year survival(P=0.018),rather than with tumor size,age of the patients or the state of estrogen receptor and progesterone receptor.Conclusions The high expression of Sox2 may be involved in the occurrence and development of breast carcinoma.The expression of Sox2 is not only associated with clinicopathological factors in breast carcinoma,but is likely to be a potential therapeutic target and a valuable prognostic indicator in breast carcinoma progression.